Two large trials, DREAM and MENSA have found IL-5 therapy with mepolizumab to lower risk of exacerbation in patients with asthma with an eosinophilic phenotype.
Research reported online in July Nature Genetics identifies a new genetic and molecular pathway in the esophagus that causes eosinophilic esophagitis (EoE).
EoE is triggered by allergic hypersensitivity to certain foods and an accumulation of eosinophils in the esophagus. It causes difficulty swallowing, tissue scarring, fibrosis and strictures.
A molecular pathway specific to epithelia tissue in the esophagus that involves a gene called calpain14 (CAPN14) has been identified. It becomes upregulated in the disease process leading to IL-13. This new gene finding opens up new therapeutic possibilities.
EoE usually responds to corticosteroid therapy. However, some trial participants did not respond to fluticasone providing evidence of EoE steroid resistance. Analyzing gene expression in esophageal tissues may help predict steroid responsiveness.
You Might Also Enjoy...
Two large trials, DREAM and MENSA have found IL-5 therapy with mepolizumab to lower risk of exacerbation in patients with asthma with an eosinophilic phenotype.
Mold allergy is difficult to diagnose due to lack of standardized test material.
The current standard for diagnosis of Eosinophilic Esophagitis (EoE) is endoscopy with esophageal biopsy to determine the eosinophil count
Skin prick testing and serum IgE measurement are limited in their ability to predict positive or negative responses to oral peanut challenge.
Bronchial Thermoplasty (BT) has been shown to result in significant improvements in a number of asthma control measures in three randomized clinical trials in patients with moderate-to-severe, persistent asthma.
Recent studies have suggested that early regular exposure to allergenic foods may reduce the risk of food allergy.